Longevity Peptides

Longevity peptides target mechanisms hypothesized to slow biological aging — mitochondrial function, immune senescence, telomere maintenance, pineal regulation, and circadian repair. The evidence base is uneven: some compounds (Thymosin Alpha-1, MOTS-c) have substantial published literature; others (Epithalon, Cortagen, Pinealon) sit primarily in Russian-language clinical reports with limited Western replication.

Pineal and Bioregulator Peptides

The Khavinson school of Russian gerontology developed a family of short bioregulator peptides — Epithalon (telomerase induction), Pinealon, Cortagen, and Thymalin. The Russian clinical literature is substantial but the Western-language replication record is limited. These compounds are widely sold in the research market based on the Russian evidence base.

Mitochondrial-Derived Peptides

MOTS-c and Humanin are mitochondrial-derived peptides with growing pre-clinical literature on metabolic regulation and senescence resistance. These are among the most actively researched longevity targets in academic settings.

Immune-Senescence Modulators

Thymosin Alpha-1 is the longevity-category overlap with healing peptides — it is FDA-approved in some jurisdictions for hepatitis and immune indications, and is widely used off-label for immune senescence. The published literature is the strongest in this category.

NAD+ and Adjacent Compounds

NAD+ injectable preparations are not peptides — they are nucleotide co-enzymes — but they cluster in the longevity research ecosystem and are sold by many peptide vendors. The pharmacokinetics of injected NAD+ are very different from peptide pharmacokinetics.

Quality Risk for Longevity Peptides

Longevity peptides face a specific quality risk: many are short oligopeptides (Epithalon is a tetrapeptide; Pinealon is a tripeptide) that are trivial to synthesize and trivial to misidentify. Mass-spec verification matters more in this category than in any other. Among our ranked vendors, Oath Peptides publishes mass-spec confirmation on the longevity catalog — a differentiator that most vendors do not match.

Procurement Framework

For longevity research, supplier quality matters more than supplier price — bad material in this category often means a different molecule entirely, not just reduced purity. See 'is premium worth it' for the cost-benefit analysis specific to this category, and the longevity peptides guide for protocol context.